PT-141 (Bremelanotide): Benefits, Dosage, Side Effects, and How to Get It
Medically reviewed by the Rite Aid Health Team · Last updated June 16, 2026
PT-141, known generically as bremelanotide, is a melanocortin-receptor agonist studied and used for low sexual desire and arousal. Unlike erectile-dysfunction drugs such as Viagra, which act on blood flow, PT-141 works through the central nervous system — it acts on the brain to increase sexual desire.
It is the rare peptide in this section with full FDA approval: it is marketed as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. If you're comparing it with non-sexual-health peptides, start with our peptide therapy guide.
Almost done
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
What is PT-141?
PT-141 (bremelanotide) is a synthetic peptide that activates melanocortin receptors in the brain. It was developed from research on melanotan, a peptide originally studied for skin tanning, when investigators observed effects on sexual arousal.
The FDA approved bremelanotide as Vyleesi in 2019 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of the few peptides in this category with a defined, approved clinical indication.
Benefits and uses
PT-141 is used for sexual dysfunction in both men and women, with the strongest formal evidence in women:
- Low sexual desire. The FDA-approved indication (as Vyleesi) is HSDD in premenopausal women — low desire that causes distress and is not attributable to another condition or medication.
- Sexual arousal. Because it acts centrally, it is studied for arousal and desire rather than the mechanical, blood-flow effect of PDE5 inhibitors.
- Use in men. PT-141 is used off-label and in research for low libido and sexual dysfunction in men, including cases where blood-flow-targeting drugs are insufficient.
The distinction from Viagra is the key point: PT-141 works through the brain, not the vascular system, which is why it addresses desire rather than only the physical mechanics of erection.
How it works
PT-141 activates melanocortin receptors (primarily MC4R) in the central nervous system. These receptors are part of the brain's regulation of sexual response.
By stimulating this pathway, PT-141 increases sexual desire and arousal centrally — a mechanism distinct from PDE5 inhibitors like sildenafil (Viagra), which act peripherally on blood vessels to enable erection. This is why PT-141 is used for desire and arousal problems that blood-flow drugs do not address.
Dosage and administration
As the FDA-approved Vyleesi, bremelanotide is given by subcutaneous injection with an auto-injector, taken on demand at least 45 minutes before anticipated sexual activity, with a defined maximum dosing frequency.
Nasal administration is also used outside the approved product. Because an approved product with official labeling exists, dosing should follow that labeling or a prescribing provider's direction — do not extrapolate from informal protocols.
Use the peptide dosage calculator when working with a non-Vyleesi formulation to convert a target dose into the right volume.
Side effects and safety
Because bremelanotide is FDA-approved, its safety profile is documented. The most common side effects reported in trials of Vyleesi are nausea (the most frequent), flushing, injection-site reactions, and headache.
A transient increase in blood pressure and decrease in heart rate occurs after dosing, so it is not recommended for people with uncontrolled high blood pressure or cardiovascular disease. Use should be guided by a provider who can review cardiovascular risk.
How to get PT-141 in 2026
PT-141's access path differs from the reclassified peptides in this section because an FDA-approved product exists:
- Vyleesi is FDA-approved for HSDD in premenopausal women and is available by prescription.
- For uses outside that indication, PT-141 is accessed off-label or through licensed compounding pharmacies by prescription.
- Products sold online "for research use only" are not manufactured or quality-controlled for human use, and buying them carries both quality and legal risk.
Rite Aid is preparing peptide consultations. Join the waitlist to claim 20% off your first PT-141 order when consultations and ordering open.
Almost done
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
PT-141 vs Viagra and other options
The most common comparison is PT-141 versus PDE5 inhibitors like Viagra (sildenafil). Viagra and similar drugs act on blood flow to enable erection but do nothing for desire; PT-141 acts centrally to increase desire and arousal.
The two address different parts of the sexual-response cycle and are sometimes considered together.
For broader hormonal contributors to libido, see the blood-work section below; for growth-hormone peptides used in performance and vitality protocols, see Sermorelin and Ipamorelin.
Blood work to track PT-141
Low libido often has a hormonal component, so a hormone baseline is the most useful workup alongside PT-141:
- Men's Hormone Health Checkup — testosterone and related hormones that factor into male libido and sexual function.
- Women's Hormone Health Checkup — the hormone panel relevant to desire and arousal in women.
Establishing a hormone baseline can clarify whether low desire is driven by a treatable hormonal factor.
Baseline tests before a peptide cycle
Check safety and response markers before starting. These tests help establish a baseline for liver, kidney, glucose, hormone, and recovery tracking.
FAQ
For low sexual desire and arousal in both men and women. As the FDA-approved Vyleesi, its specific indication is hypoactive sexual desire disorder (HSDD) in premenopausal women.
Viagra (sildenafil) acts on blood flow to enable an erection; PT-141 acts through the central nervous system to increase sexual desire and arousal. PT-141 addresses desire, which blood-flow drugs do not.
Yes. Bremelanotide is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women. Other uses are off-label.
As Vyleesi, it is a subcutaneous injection taken on demand at least 45 minutes before anticipated activity, with a defined maximum frequency. Dosing should follow the approved labeling or a prescribing provider.
The most common is nausea, followed by flushing, injection-site reactions, and headache. It causes a transient rise in blood pressure and is not recommended for people with uncontrolled hypertension or cardiovascular disease.
It is used off-label and in research for low libido and sexual dysfunction in men, including cases where blood-flow-targeting drugs are insufficient. Its FDA approval is specific to premenopausal women.